Although low‐dose cyclophosphamide has demonstrated effectiveness in enhancing antigen‐specific CD4+ T‐cell responses to the NY‐ESO‐1/ISCOMATRIX vaccine among individuals with advanced melanoma compared to vaccination alone, it has not yielded notable reductions in Tregs.78 This evidence concerns the gene CD4 and melanoma.